Neuropsychiatry

From evidence-based novel therapies for bipolar depression to potential indicators of early-stage Alzheimer disease, here are highlights from the week in Psychiatric Times.

The experts weighed in on a wide variety of psychiatric issues for the November 2022 issue of Psychiatric Times.

From the cross-cultural dimensions of psychosis to the economic burden of schizophrenia, here are highlights from the week in Psychiatric Times.

Noninvasive brain stimulation techniques have been shown to be safe and effective in treating the cognitive, physical, and emotional consequences of acquired brain injury.

The law presumes that individuals are rational. But what about when the patient has neuropsychiatric impairments that hinder judgement?

Beyond the COVID-19-driven shock, we must develop a resilient future in an increasingly uncertain world.

Connections between autism risk, sleep disturbances, insomnia risk genes and circadian pathways were analyzed.

Can Alzheimer disease research offer the key to effective treatment?

"Rooted in ancient meditative traditions, mind-body practices can offer simple and scalable tools of self-regulation that incorporate controlled paced breathing, which is therapeutic in alleviating symptoms of stress, anxiety, depression, and chronic pain disorders."

A reminder to cherish your parents and the older adults in your life.

From traumatic brain injury to the dangers of excessive social media usage, here are highlights from the week in Psychiatric Times.

From ketamine response to differences between mTBI and concussion, here are highlights from the week in Psychiatric Times.

Understanding the symptom overlap between concussion/mild traumatic brain injury and other psychiatric conditions, such as PTSD and depression, can assist clinicians in differential diagnosis and providing effective treatment.

What's the best way to manage headaches and psychiatric disorders?

A transdisciplinary team summarizes key points and reflections after 18 months of activity.

"It would be naïve to believe that targeting a single neurotransmitter, receptor, or circuit in the brain will cure any psychiatric or neurological disorder. However, we would be remiss if we did not try."

The experts weighed in on a wide variety of psychiatric issues for the August 2022 issue of Psychiatric Times.

These are the extra figures for John J. Miller, MD's article, "Serotonin: A Biography" from the 2022 September issue.

What are the long term psychiatric and neuropsychiatric complications of COVID-19?

Is the term, "extrapyramidal symptoms," an example of a “4-letter word”?

An estimated 5% to 10% of acute psychiatric inpatients have catatonia—yet catatonia remains widely underdiagnosed.

Survey results addressed connections between migraine and mental health, stigma, and treatment preferences.

Is our research about Alzheimer disease wrong?

How prioritizing brain health and brain skills could offer new solutions to this challenge.

"The young and exciting field of psychiatric pharmacogenomics is providing a third pillar of understanding to aid in our competent and informed prescribing of drugs, joining the more well-established pillars of pharmacokinetics and pharmacodynamics."